Market Overview

Corbus Pharmaceuticals: Q3 Earnings Insights



Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 34.37% year over year to ($0.43), which missed the estimate of ($0.42).

Revenue of $1,231,000 decreased by 52.47% from the same period last year, which missed the estimate of $2,310,000.


Corbus Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $9.78

52-week low: $0.91

Price action over last quarter: down 81.85%

Company Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.


Related Articles (CRBP)

View Comments and Join the Discussion!

Posted-In: Earnings News